How science is finally making real progress in treating allergies—and what it means for you
After decades of limited options, allergy care is may no longer a one-size-fits-all treatment approach.
Every spring, millions of allergy sufferers fall into the same familiar routine of checking pollen counts, bracing for congestion, and reaching for medications that promise relief.
But their options are expanding like never before as a wave of new research and therapies are “moving beyond a ‘one-size-fits-all’ approach,” says DeVon Preston, an allergist at Cleveland Clinic—shifting care away from simply treating symptoms toward changing how the body responds to allergens in the first place.
And “there are even more exciting therapies in the pipeline,” adds Scott Sicherer, director of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai.
He says these include patches and tablets that expose the immune system to allergens in new and exciting ways, as well as emerging treatments designed to “teach the immune system not to attack certain food proteins.”
(What you need to know about food allergies)
These and other shifts in research and care could reshape allergy treatment for current and future generations of allergy sufferers alike.
From managing symptoms to retraining the immune system
At its core, an allergic reaction is a case of mistaken identity, as the immune system flags as dangerous something usually recognized as harmless, such as pollen, pet dander, or a food protein. When this happens, allergens trigger inflammation and symptoms such as sneezing, itching, congestion, or swelling.
Complicating matters, “many patients with allergies often have more than one allergic disease,” says Robert Wood, director of the Eudowood Division of Pediatric Allergy, Immunology, and Rheumatology at Johns Hopkins Children’s Center, noting overlaps between asthma, eczema, and food allergies.
In individual and multi-front cases, traditional treatments are commonly administered after symptoms begin. Antihistamines block histamine—a key chemical involved in allergic responses—while corticosteroids reduce inflammation. But neither addresses the underlying immune dysfunction.
By contrast, “modifying the immune system," Preston explains, "aims to retrain or desensitize the allergic immune system to tolerate allergens." This is typically done by exposing the body to very small, gradually increasing amounts of an allergen—helping the immune system learn to respond more calmly “and actually altering the immune system, making it less allergic,” says Dale Umetsu, an allergist and immunologist at UCSF Health.
But this approach, known as immunotherapy, isn’t entirely new as allergy shots have used a version of it for decades. What’s changing now is how immunotherapy is tailored and delivered as newer approaches can be more convenient (like tablets taken at home instead of injections), safer for some patients, shorter-term in use, and more precisely targeted to an individual’s biology.
So rather than replacing allergy shots, these innovations expand options—especially for people who can’t tolerate or access traditional treatments.
New ways of delivering immunotherapy
Some of the biggest changes are happening in food allergy care where treatment has historically meant strict avoidance and being prepared for emergencies. But newer therapies aim to build tolerance instead.
(How cutting out certain foods can trigger new allergies)
Oral immunotherapy, for example, involves giving “tiny and then gradually increasing amounts of the food” to train the immune system to tolerate it, Sicherer says.
Other approaches are also emerging. “Food drops under the tongue and the use of patches containing food proteins” especially show promise, says Matthew Rank, a physician who works in the division of allergy, asthma and clinical immunology at Mayo Clinic in Arizona.
Even traditional immunotherapy is evolving. New tablets that are often used for grass or ragweed allergies offer a more convenient alternative to injections and can be taken at home.
These and other therapies “work similarly to traditional allergy shots by inducing tolerance,” says Purvi Parikh, an allergist and immunologist at NYU Langone Health.
Doctors are also tailoring treatments based on a patient’s biology. In asthma, for instance, some patients have what’s known as “T2 inflammation,”—an immune response driven by specific cells and molecules in the airways—while others do not. A distinction that directly affects which treatments works best.
“Personalized medicine now also includes optimizing treatments based on lifestyle, environment, diagnostic testing, and individual risk,” Umetsu adds. These matter because sensitivity levels can vary greatly. “Some patients react to trace exposures, while others tolerate more,” Sicherer explains.
Meanwhile, researchers are also exploring mRNA-based allergy vaccines—an approach that could one day reprogram the immune system to tolerate allergens before symptoms even begin.
Still, such treatments are currently "experimental and need to be shown to be safe and effective,” cautions Umetsu.
More precise and personalized therapies
But among the most talked-about advances are engineered antibodies known as biologics, that target specific parts of the immune system—treatments that are typically delivered as injections in a doctor’s office or at home.
Recent research, including a 2025 clinical trial, has examined biologic drugs such stapokibart, which block key immune signals involved in allergic inflammation. These signals—called cytokines and interleukins—act as messengers that trigger allergic reactions. By blocking them, biologics can interrupt the allergic response at its source.
The results are promising as even during pollen season, the study found that 64 percent of participants reported mild or no symptoms. A 2026 review similarly highlights how biologics are transforming care by targeting the precise pathways that drive allergic reactions.
And although these and other early studies have been relatively small (some involving fewer than 100 participants), larger trials are ongoing, and many experts see these results as a strong proof of concept rather than a limitation in scalability.
“In my four decades as a pediatric allergist," says Wood, "very little changed until the past few years when the introduction of biologics completely changed our approach for many patients."
It’s also important to note, adds Umetsu, that although primarily researched and FDA approved for food allergy exposure alone, “biologics such as omalizumab can also be effective for inhaled allergies such as grass or tree pollen.” In fact, other countries have already approved them for such uses.
And biologics and allergy shots each have distinct advantages. “Allergy shots still have more long-lasting, disease-modifying effects than any biologic,” Wood says. At the same time, allergy shots generally require a much longer term of treatment.
Another distinction is that “allergy shots build tolerance to an allergen, while biologics block specific immune signals rather than suppressing the entire system," explains Parikh.
So rather than competing, these treatments may work best together as combining biologics with immunotherapy “likely improves safety and effectiveness," says Rank.
There’s no single ‘allergy season’
For allergy sufferers, especially those with severe symptoms, many of these advances are reshaping expectations as the goal is no longer just to survive allergy season, but to change how the body responds to and prepares against it.
That’s especially important because “allergy season” isn’t the same for everyone.
For instance, Woods notes that while many people react to seasonal triggers such as tree pollen in spring, grass in summer, or ragweed in fall, others are sensitive to year-round allergens like dust mites, pet dander, or mold. For these individuals, “‘allergy season’ can be year-round,” Parikh says.
Geography also plays a role. “Environmental allergies depend on time of year and location,” Rank explains, which is why clinicians increasingly rely on pollen data and symptom patterns to further guide care.
But challenges remain as affordability and accessibility for new treatments options can be barriers, and finding the right treatment can also take time. “This can be a remarkably diverse process, depending on the patient,” Preston says.
Even so, progress is accelerating. “There has been a huge shift to active approaches that are incredibly exciting,” Sicherer says.
And the stakes are high. “Many people don’t realize that allergies can be life-threatening,” Parikh notes, pointing out that allergy-related asthma attacks alone lead to thousands of preventable deaths each year.
"This makes this a very exciting time to be treating allergies,” she says, as the range of treatment options has never been broader, and “we can tailor treatments to individuals and really improve their quality of life and even save their lives."
